Key result
Bisphosphonate therapy significantly prolonged the median time to the first skeletal-related event compared to no bisphosphonates (5 vs 2 months, P=0.002) in patients with soft tissue sarcoma.
Why the study?
Do bisphosphonates delay skeletal related events in patients with soft tissue sarcoma and bone metastases?
Population
135 patients affected by soft tissue sarcoma (STS) with bone metastases
Comparison
Bisphosphonates (evaluated in a subgroup analysis) vs No bisphosphonates (implied in subgroup analysis)
Design
Cohort
Authors
Loading...
May support bisphosphonate use to delay skeletal events in soft tissue sarcoma; hypothesis-generating and requires randomized confirmation.
Observational (n=135)
Yes
Do bisphosphonates delay skeletal related events in patients with soft tissue sarcoma and bone metastases?
Absolute Event Rate: 5% vs 2%
p-value: p=0.002
In patients with soft tissue sarcoma and bone metastases, bisphosphonates significantly delay the onset of skeletal-related events.
Vincenzi et al. (2013) conducted an observational in Soft tissue sarcoma with bone metastases (n=135). Bisphosphonates vs. No bisphosphonates was evaluated on Median time to first skeletal-related event (SRE) in months (p=0.002). Bisphosphonate therapy significantly prolonged the median time to the first skeletal-related event compared to no bisphosphonates (5 vs 2 months, P=0.002) in patients with soft tissue sarcoma.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: